Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (A) levels in human subjects with rheumatoid diseases

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Schultz, Olaf ^a   Oberhauser, Frank ^a   Saech, Jasemine ^a   Rubbert Roth, Andrea ^a   Hahn, Moritz ^b   Krone, Wilhelm ^a   Laudes, Matthias ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALENDRONIC ACID; ALLOPURINOL; COLCHICINE; ENALAPRIL; ESOMEPRAZOLE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LEFLUNOMIDE; LEPTIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; METHYLPREDNISOLONE; OMEPRAZOLE; PANTOPRAZOLE; PHENPROCOUMON; PREDNISONE; SIMVASTATIN; TOCILIZUMAB; TORASEMIDE; TRIACYLGLYCEROL; ADIPOCYTOKINE; CYTOKINE; INSULIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RHEUMATIC DISEASE; RISK REDUCTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; METABOLISM; MIDDLE AGED; RHEUMATOID ARTHRITIS;

ADIPOKINES; ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; LIPOPROTEIN(A); MALE; MIDDLE AGED; SIGNAL TRANSDUCTION;

EID: 78650781728     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014328     Document Type: Article

References (44)

1. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW (2009) Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 94: 1853-1878.
2. Katagiri H, Yamada T, Oka Y (2007) Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 101: 27-39.
3. Yamagishi S, Nakamura K, Matsui T, Takenaka K, Jinnouchi Y, et al. (2006) Cardiovascular disease in diabetes. Mini Rev Med Chem 6: 313-318.
4. Skurk T, Alberti-Huber C, Herder C, Hauner H (2007) Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92: 1023-1033.
5. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116: 1494-1505.
6. Xu H, Sethi JK, Hotamisligil GS (1999) Transmembrane tumor necrosis factor (TNF)-alpha inhibits adipocyte differentiation by selectively activating TNF receptor 1. J Biol Chem 274: 26287-26295.
7. Sethi JK, Xu H, Uysal KT, Wiesbrock SM, Scheja L, et al. (2000) Characterisation of receptor-specific TNFalpha functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. FEBS Lett 469: 77-82.
8. Siddiqui MA, Scott LJ (2005) Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 65: 2179-2208.
9. Voulgari PV, Drosos AA (2006) Adalimumab for rheumatoid arthritis. Expert Opin Biol Ther 6: 1349-1360.
10. Oldfield V, Plosker GL (2009) Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs 23: 125-135.
11. Patel AM, Moreland LW (2010) Certolizumab pegol: a new biologic targeting rheumatoid arthritis. Expert Rev Clin Immunol 16: 855-866.
12. Wiens A, Correr CJ, Pontarolo R, Venson R, Quinalha JV, et al. (2009) A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scand J Immunol 70: 337-344.
13. Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 36: 1118-1125.
14. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK (2007) Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 36: 91-96.
15. Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, et al. (2005) Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42: 517-525.
16. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, et al. (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356: 1517-1526.
17. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, et al. (2001) Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86: 1154-1159.
18. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, et al. (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112: 3959-3964.
19. Takahashi M, Funahashi T, Shimomura I, Miyaoka K, Matsuzawa Y (1996) Plasma leptin levels and body fat distribution. Horm Metab Res 28: 751-752.
20. Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, et al. (2009) Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia 52: 2345-2349.
21. Kawashiri SY, Kawakami A, Yamasaki S, Imazato T, Iwamoto N, et al. (2009) Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int, epub.
22. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745-751.
23. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, et al. (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52: 812-817.
24. Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, et al. (2006) IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes 55: 2915-2921.
25. Kristiansen OP, Mandrup-Poulsen T (2005) Interleukin-6 and Diabetes. Diabetes 54: S114-S124.
26. Hamid YH, Rose CS, Urhammer SA, Glümer C, Nolsøe R, et al. (2005) Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia 48: 251-260.
27. Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, et al. (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75-79.
28. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA (2004) Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 287: E182-187.
29. Klover PJ, Clementi AH, Mooney RA (2005) Interleukin-6 depletion selectively improves hepatic insulin action in obesity Endocrinology 146: 3417-3427.
30. Glund S, Krook A (2008) Role of interleukin-6 signalling in glucose and lipid metabolism. Acta Physiol (Oxf) 192: 37-48.
31. Kamimura D, Ishihara K, Hirano T (2003) IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149: 1-38.
32. Rieusset J, Bouzakri K, Chevillotte E, Ricard N, Jacquet D, et al. (2004) Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 53: 2232-2241.
33. Maggio M, Guralnik JM, Longo DL, Ferrucci L (2006) Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 61: 575-584.
34. Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, et al. (2010) Associations between leptin and the leptin/adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA/KORA Augsburg study 1984-2002 Diabet Med 27: 1004-1011.
35. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, et al. (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58: 2968-2980.
36. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, et al. (2006) Doubleblind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54: 2817-2829.
37. Danesh J, Collins R, Peto R (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102: 1082-1085.
38. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, et al. (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330: 132-137.
39. Sangrar W, Bajzar L, Nesheim ME, Koschinsky ML (1995) Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry 34: 5151-5157.
40. Dangas G, Mehran R, Harpel PC, Sharma SK, Marcovina SM, et al. (1998) Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 32: 2035-2042.
41. Lawn RM (1996) How often has Lp(a) evolved? Clin Genet 49: 167-174.
42. Yun KA, Lee W, Min WK, Chun S, Lee YW, et al. (2004) Discrepancy of interleukin-6 levels between end-stage renal disease patients and patients with acute-phase response with increased lipoprotein(a) concentrations. Scand J Clin Lab Invest 64: 223-228.
43. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52: 722-732.
44. Ogata A, Morishima A, Hirano T, Hishitani Y, Hagihara K, et al. (2010) Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis Epub ahead of print.